Combination therapy for the treatment of executive function disorders
A combination of lacosamide and oxcarbazepine addresses the limitations of molecular stimulants by providing long-term symptom management for ADHD and autism with reduced side effects and no tolerance, effectively treating executive dysfunction.
Patent Information
- Application Number
- JP2023547057
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-02-03
- Filing Date
- 2022-02-03
- Publication Date
- 2026-07-02
- Estimated Expiration
- 2042-02-03
AI Technical Summary
Current treatments for executive function disorders such as ADHD and autism, particularly those involving molecular stimulants like methylphenidate, are associated with significant side effects, addiction risks, and develop tolerance over time, making them unsuitable for long-term administration.
A combination therapy using lacosamide or a functionally equivalent analogue and oxcarbazepine or a functionally equivalent analogue, administered simultaneously, separately, or sequentially, to address the underlying causes of executive dysfunction without stimulating neurotransmitter release or reuptake, thereby providing long-term symptom management.
The combination therapy effectively reduces symptoms of executive dysfunction, including hyperactivity, impulsivity, and other related issues, with minimal side effects and no tolerance development, offering progressive and long-term stabilization.